MUC5AC and neoplasm: Similar findings were obtained when CD13+ spheroids were implanted, since the tumor volume remained almost stable following the treatment with NVP-BEZ235 (740 ± 100 mm3 for mixed-IHCCA and 650 ± 94 mm3 for mucin-IHCCA, Fig 7B, p< 0.05 vs controls) or Abraxane (670 ± 90 mm3 for mixed-IHCCA and 720 ± 85 mm3 for mucin-IHCCA, p< 0.05 vs controls).